



## **PROBIOTEC LIMITED**

**ABN 91 075 170 151**

83 Cherry Lane  
Laverton North, VIC 3026  
AUSTRALIA

Phone: + 61 3 9278 7555  
Fax: + 61 3 9369 6730

[www.probiotec.com.au](http://www.probiotec.com.au)

### **ASX ANNOUNCEMENT**

30 May 2016

#### **PROBIOTEC COMPLETES CLINICAL TRIALS ON ECZEMA AND GENE EXPRESSION**

The directors of Probiotec Limited (ASX: PBP) ("the Company") are pleased to announce that the Company has recently completed and received results with respect to two separate clinical trials it has run over the past 12 months. These trials were embarked upon by the Company to examine the effect of its specific protein fraction (Glycomax™):

- against atopic dermatitis (more commonly known as eczema); and
- to assess its wider impact on changes in gene expression to examine the effect this compound may have on various disease states.

#### **Gene Expression Trial**

Probiotec CEO Mr Wesley Stringer stated that "the gene expression trial has provided exciting results in relation to inflammatory regulation that has the potential translation to a wide range of fields with particular application to the infant, aged and functional nutrition categories".

Dr Amanda Cox, Senior Research Fellow in the Mucosal Immunology Research Group at Griffith University, notes that "the outcomes of the trial, designed to examine changes in molecular pathways to guide future clinical research and applications, are promising in relation to healthy aging".

#### **Atopic Dermatitis (eczema) Trial**

The Company welcomes this new and exciting clinical evidence obtained via its phase II study. The study, conducted in collaboration with Griffith University and the St George Dermatology and Skin Cancer Centre in a joint clinical trial, was undertaken to determine whether the compound had sufficient activity for use in atopic dermatitis.

The finding of the study was significant for the number of patients that had an improvement in their symptoms during supplementation, a proportion that was double the pre-specified clinical threshold and that indicates this protein fraction is a promising alternative to standard care.

Professor Allan Cripps, Pro-Vice Chancellor (Health) at Griffith University and one of the principal scientists of the study said "a reduction in symptoms indicates that this supplement may improve quality of life for those people suffering with eczema".

Probiotec Ltd CEO Mr Wesley Stringer said "the results of the trial are exciting for the business and the development of our Glycomax™ fraction is consistent with the company's objective of investing in the development of new intellectual property around innovative health solutions for use in the contract manufacturing of our partners' brands".

The Company has lodged patent applications to protect its intellectual property position.

Mr Stringer also stated that the Company would now be looking at options to commercialise these results with a suitable partner in the immediate future.

For further information, please contact:

Wesley Stringer  
CEO  
+61 3 9278 7555  
-----

**About Probiotec**

Probiotec Limited is a brand owner, manufacturer, marketer and distributor of a range of prescription and over-the-counter (OTC) pharmaceuticals, complementary medicines and specialty ingredients. The company distributes its products both domestically and internationally. Products are manufactured by Probiotec for both its own products and on behalf of others, including major international pharmaceutical companies.

Further details about Probiotec are available at [www.probiotec.com.au](http://www.probiotec.com.au).

For further information contact:

Mr Wesley Stringer, Managing Director  
+61 3 9278 7555